199 related articles for article (PubMed ID: 22995650)
21. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study.
Cappuzzo F; Ciuleanu T; Stelmakh L; Cicenas S; Szczésna A; Juhász E; Esteban E; Molinier O; Brugger W; Melezínek I; Klingelschmitt G; Klughammer B; Giaccone G;
Lancet Oncol; 2010 Jun; 11(6):521-9. PubMed ID: 20493771
[TBL] [Abstract][Full Text] [Related]
22. Lack of effect of aprepitant on the pharmacokinetics of docetaxel in cancer patients.
Nygren P; Hande K; Petty KJ; Fedgchin M; van Dyck K; Majumdar A; Panebianco D; de Smet M; Ahmed T; Murphy MG; Gottesdiener KM; Cocquyt V; van Belle S
Cancer Chemother Pharmacol; 2005 Jun; 55(6):609-16. PubMed ID: 15723220
[TBL] [Abstract][Full Text] [Related]
23. Topical non-peptide antagonists of sensory neurotransmitters substance P and CGRP do not modify patch test and prick test reactions: a vehicle-controlled, double-blind pilot study.
Wallengren J; Edvinsson L
Arch Dermatol Res; 2014 Jul; 306(5):505-9. PubMed ID: 24525842
[TBL] [Abstract][Full Text] [Related]
24. Antihistamines-refractory chronic pruritus in psoriatic patients undergoing biologics: aprepitant vs antihistamine double dosage, a real-world data.
Damiani G; Kridin K; Pacifico A; Malagoli P; Pigatto PDM; Finelli R; Taccone FS; Peluso L; Conic RRZ; Bragazzi NL; ; Fiore M
J Dermatolog Treat; 2022 May; 33(3):1554-1557. PubMed ID: 33084462
[TBL] [Abstract][Full Text] [Related]
25. Aprepitant: a neurokinin-1 receptor antagonist for the treatment of chemotherapy-induced nausea and vomiting.
Navari RM
Expert Rev Anticancer Ther; 2004 Oct; 4(5):715-24. PubMed ID: 15485308
[TBL] [Abstract][Full Text] [Related]
26. Glioblastoma: synergy of growth promotion between CCL5 and NK-1R can be thwarted by blocking CCL5 with miraviroc, an FDA approved anti-HIV drug and blocking NK-1R with aprepitant, an FDA approved anti-nausea drug.
Kast RE
J Clin Pharm Ther; 2010 Dec; 35(6):657-63. PubMed ID: 21054456
[TBL] [Abstract][Full Text] [Related]
27. Substance P Antagonist Aprepitant Shows no Additive Effect Compared with Standardized Topical Treatment Alone in Patients with Atopic Dermatitis.
Lönndahl L; Holst M; Bradley M; Killasli H; Heilborn J; Hall MA; Theodorsson E; Holmberg J; Nordlind K
Acta Derm Venereol; 2018 Mar; 98(3):324-328. PubMed ID: 29182791
[TBL] [Abstract][Full Text] [Related]
28. Aprepitant when added to a standard antiemetic regimen consisting of ondansetron and dexamethasone does not affect vinorelbine pharmacokinetics in cancer patients.
Loos WJ; de Wit R; Freedman SJ; Van Dyck K; Gambale JJ; Li S; Murphy GM; van Noort C; de Bruijn P; Verweij J
Cancer Chemother Pharmacol; 2007 Feb; 59(3):407-12. PubMed ID: 17051369
[TBL] [Abstract][Full Text] [Related]
29. Need for Flexible Adjustment of the Treatment Schedule for Aprepitant Administration against Erlotinib-Induced Refractory Pruritus and Skin Rush.
Seki N; Ochiai R; Haruyama T; Ishihara M; Natsume M; Fukasawa Y; Sakamoto T; Tanzawa S; Usui R; Honda T; Ota S; Ichikawa Y; Watanabe K
Case Rep Oncol; 2019; 12(1):84-90. PubMed ID: 30792647
[TBL] [Abstract][Full Text] [Related]
30. Rationale and design of the multicentric, double-blind, double-placebo, randomized trial APrepitant versus HYdroxyzine in association with cytoreductive treatments for patients with myeloproliferative neoplasia suffering from Persistent Aquagenic Pruritus. Trial acronym: APHYPAP.
Le Gall-Ianotto C; Verdet R; Nowak E; Le Roux L; Gasse A; Fiedler A; Carlhant-Kowalski D; Marcorelles P; Misery L; Ianotto JC
Trials; 2021 Dec; 22(1):938. PubMed ID: 34923994
[TBL] [Abstract][Full Text] [Related]
31. Itch in Atopic Dermatitis Management.
Kamata Y; Tominaga M; Takamori K
Curr Probl Dermatol; 2016; 50():86-93. PubMed ID: 27578076
[TBL] [Abstract][Full Text] [Related]
32. More on aprepitant for erlotinib-induced pruritus.
Mir O; Blanchet B; Goldwasser F
N Engl J Med; 2011 Feb; 364(5):487. PubMed ID: 21288111
[No Abstract] [Full Text] [Related]
33. Aprepitant against pruritus in patients with solid tumours.
Vincenzi B; Fratto ME; Santini D; Tonini G
Support Care Cancer; 2010 Sep; 18(9):1229-30. PubMed ID: 20544226
[No Abstract] [Full Text] [Related]
34. Aprepitant in Anti-histamine-refractory Chronic Nodular Prurigo: A Multicentre, Randomized, Double-blind, Placebo-controlled, Cross-over, Phase-II trial (APREPRU).
Tsianakas A; Zeidler C; Riepe C; Borowski M; Forner C; Gerss J; Metz M; Staubach P; Raap U; Kaatz M; Urban M; Luger TA; Ständer S
Acta Derm Venereol; 2019 Apr; 99(4):379-385. PubMed ID: 30653242
[TBL] [Abstract][Full Text] [Related]
35. The effect of desonide hydrogel on pruritis associated with atopic dermatitis.
Kircik L
J Drugs Dermatol; 2014 Jun; 13(6):725-8. PubMed ID: 24918564
[TBL] [Abstract][Full Text] [Related]
36. Role of Substance P and Its Receptor Neurokinin 1 in Chronic Prurigo: A Randomized, Proof-of-Concept, Controlled Trial with Topical Aprepitant.
Ohanyan T; Schoepke N; Eirefelt S; Hoey G; Koopmann W; Hawro T; Maurer M; Metz M
Acta Derm Venereol; 2018 Jan; 98(1):26-31. PubMed ID: 28853492
[TBL] [Abstract][Full Text] [Related]
37. Randomized, placebo-controlled, pilot study evaluating aprepitant single dose plus palonosetron and dexamethasone for the prevention of acute and delayed chemotherapy-induced nausea and vomiting.
Herrington JD; Jaskiewicz AD; Song J
Cancer; 2008 May; 112(9):2080-7. PubMed ID: 18327813
[TBL] [Abstract][Full Text] [Related]
38. Treatment of pruritus with topically applied opiate receptor antagonist.
Bigliardi PL; Stammer H; Jost G; Rufli T; Büchner S; Bigliardi-Qi M
J Am Acad Dermatol; 2007 Jun; 56(6):979-88. PubMed ID: 17320241
[TBL] [Abstract][Full Text] [Related]
39. More on aprepitant for erlotinib-induced pruritus.
Gerber PA; Buhren BA; Homey B
N Engl J Med; 2011 Feb; 364(5):486-7. PubMed ID: 21288112
[No Abstract] [Full Text] [Related]
40. Aprepitant in adolescent patients for prevention of chemotherapy-induced nausea and vomiting: a randomized, double-blind, placebo-controlled study of efficacy and tolerability.
Gore L; Chawla S; Petrilli A; Hemenway M; Schissel D; Chua V; Carides AD; Taylor A; Devandry S; Valentine J; Evans JK; Oxenius B;
Pediatr Blood Cancer; 2009 Feb; 52(2):242-7. PubMed ID: 18985740
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
